165 related articles for article (PubMed ID: 37168513)
1. Dynamics of CD4
Zhang W; Liu S; Miao L; Fu A; Bao J; Zheng L; Li E; Yu J; Wang Y
Infect Drug Resist; 2023; 16():2695-2707. PubMed ID: 37168513
[TBL] [Abstract][Full Text] [Related]
2. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
[TBL] [Abstract][Full Text] [Related]
4. A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV.
Lv Z; Lv S; Li Q; Xia Y; Feng Z; Zhang H; Yang H; Wu Z; Zou N; Mo Q; Gu Q; Ying S; Wang X; Qin D; Wan C
Front Immunol; 2023; 14():1264160. PubMed ID: 38045691
[TBL] [Abstract][Full Text] [Related]
5. IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China.
Zeng G; Xu L; Feng S; Tang J; Wang X; Li G; Gan Y; Zheng C; Zhao J; Yang Z
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746488
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
Li J; Nie L; Guo C; Deng Y; Guo Q; Pang C; Xin R; Li J; Lu H; Huang C
J Med Virol; 2023 Dec; 95(12):e29334. PubMed ID: 38140842
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study.
Feng Y; Zhang Y; He Z; Huang H; Tian X; Wang G; Chen D; Ren Y; Jia L; Wang W; Wu J; Shao L; Zhang W; Tang H; Wan Y
EClinicalMedicine; 2022 Jan; 43():101226. PubMed ID: 34901799
[TBL] [Abstract][Full Text] [Related]
8. Humoral Immune Response to Inactivated COVID-19 Vaccination at the 3rd Month among People Living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
Res Sq; 2022 Jun; ():. PubMed ID: 35794897
[No Abstract] [Full Text] [Related]
9. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
[TBL] [Abstract][Full Text] [Related]
10. Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.
Wang Y; Li J; Zhang W; Liu S; Miao L; Li Z; Fu A; Bao J; Huang L; Zheng L; Li E; Zhang Y; Yu J
Front Immunol; 2023; 14():1152695. PubMed ID: 36936952
[TBL] [Abstract][Full Text] [Related]
11. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines.
Tan Y; Zou S; Ming F; Wu S; Guo W; Wu M; Tang W; Liang K
Front Immunol; 2023; 14():1174379. PubMed ID: 37404815
[TBL] [Abstract][Full Text] [Related]
12. Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China.
Han X; Yu X; Han Y; Fang Q; Shen C; Liu H; Wang P; Wang Y; Li X
Infect Drug Resist; 2022; 15():2091-2100. PubMed ID: 35480056
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Vaccine-Induced T-Cell Response after Three Doses in People Living with HIV on Antiretroviral Therapy Compared to Seronegative Controls (CTN 328 COVAXHIV Study).
Alexandrova Y; Yero A; Mboumba Bouassa RS; Comeau E; Samarani S; Brumme ZL; Hull M; Crawley AM; Langlois MA; Angel JB; Cooper CL; Needham J; Lee T; Singer J; Anis AH; Costiniuk CT; Jenabian MA
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851789
[TBL] [Abstract][Full Text] [Related]
14. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
[TBL] [Abstract][Full Text] [Related]
15. Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
Lu T; Chen Z; Cao Y; Ao L; Li Z; Gu X; Ren X; Wang Y; Zhang G; Xiang D; Chen M; Cai D; Hu P; Zhang D; Peng M; Shi X; Ren H
J Med Virol; 2023 Apr; 95(4):e28730. PubMed ID: 37185852
[TBL] [Abstract][Full Text] [Related]
16. The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.
Wang Y; Qiao Y; Huo Y; Wang L; Liang S; Yu M; Lan X; Song M; Zhang X; Yan Y; Xu J
Front Immunol; 2023; 14():1129651. PubMed ID: 36993947
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.
Ao L; Lu T; Cao Y; Chen Z; Wang Y; Li Z; Ren X; Xu P; Peng M; Chen M; Zhang G; Xiang D; Cai D; Hu P; Shi X; Zhang D; Ren H
Emerg Microbes Infect; 2022 Dec; 11(1):1126-1134. PubMed ID: 35369854
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
20. Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals.
Zou S; Wu M; Ming F; Wu S; Guo W; Marley G; Xing Z; Zhang Z; Zeng M; Sun C; Zhang J; Tang W; Liang K
AIDS Res Ther; 2022 Jul; 19(1):33. PubMed ID: 35791004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
